HuGE Literature Finder
Records
1
-
6
Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancer. Cancer 2017 Aug 123 (15): 2936-2944. Tarhini Ahmad A, Rafique Imran, Floros Theofanis, Tran Phu, Gooding William E, Villaruz Liza C, Burns Timothy F, Friedland David M, Petro Daniel P, Farooqui Mariya, Gomez-Garcia Jose, Gaither-Davis Autumn, Dacic Sanja, Argiris Athanassios, Socinski Mark A, Stabile Laura P, Siegfried Jill |
Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib. Oncotarget 2016 Aug . Rimassa Lorenza, Abbadessa Giovanni, Personeni Nicola, Porta Camillo, Borbath Ivan, Daniele Bruno, Salvagni Stefania, Van Laethem Jean-Luc, Van Vlierberghe Hans, Trojan Jörg, De Toni Enrico N, Weiss Alan, Miles Steven, Gasbarrini Antonio, Lencioni Monica, Lamar Maria E, Wang Yunxia, Shuster Dale, Schwartz Brian E, Santoro Arman |
Clinical usefulness of gefitinib for non-small-cell lung cancer with a double epidermal growth factor receptor mutation. Molecular and clinical oncology 2015 Mar 3 (2): 329-333. Oikawa Takefumi, Ohira Tatsuo, Otani Keishi, Hagiwara Masaru, Konaka Chimori, Ikeda Norihi |
Association between plasma hepatocyte growth factor and gefitinib resistance in patients with advanced non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands) 2011 Nov 74 (2): 293-9. Han Ji-Youn, Kim Jin Young, Lee Suk Hyung, Yoo Nam Jin, Choi Byung G |
MET phosphorylation predicts poor outcome in small cell lung carcinoma and its inhibition blocks HGF-induced effects in MET mutant cell lines. British journal of cancer 2011 (6): 814-23. Arriola E, Cañadas I, Arumí-Uría M, Dómine M, Lopez-Vilariño J A, Arpí O, Salido M, Menéndez S, Grande E, Hirsch F R, Serrano S, Bellosillo B, Rojo F, Rovira A, Albanell |
Somatic mutation and functional polymorphism of a novel regulatory element in the HGF gene promoter causes its aberrant expression in human breast cancer. The Journal of clinical investigation 2009 Mar 119 (3): 478-91. Ma Jihong, DeFrances Marie C, Zou Chunbin, Johnson Carla, Ferrell Robert, Zarnegar Re |
- Page last reviewed:Feb 1, 2023
- Page last updated:Feb 03, 2023
- Content source: